GlassScriptPhysician profile
Daniel H Kelly
NPI 1417480831
$3,082.83
in general payments reported to CMS, 2019-2025
29 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $29.25 · 2021: $204 · 2022: $855 · 2023: $721 · 2024: $476 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.96 | 2022-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $268.52 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $222.56 | 2022-2025 | Farxiga, Wainua, Brilinta |
| Merck Sharp & Dohme LLC | $191.77 | 2022-2025 | Verquvo |
| Amgen INC. | $190.48 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $126.72 | 2024 | |
| Abiomed | $124.97 | 2023 | Impella |
| Inari Medical, INC. | $121.42 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $119.96 | 2021-2023 | Camzyos |
| Lantheus Medical Imaging, INC. | $119.59 | 2019 | |
| Alnylam Pharmaceuticals INC. | $118.77 | 2025 | Amvuttra |
| Philips North America LLC | $112.43 | 2022 | |
| Irhythm Technologies, INC. | $110.03 | 2022-2023 | Zio Xt Patch |
| Bayer Healthcare Pharmaceuticals INC. | $108.18 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $59.44 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $54.59 | 2022-2023 | Watchman |
| Janssen Pharmaceuticals, INC | $50.37 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $45.86 | 2025 | Arexvy, Shingrix |
| Heartflow, INC. | $38.39 | 2024-2025 | |
| Medtronic, INC. | $34.53 | 2021-2025 | Aurora Ev-Icd Mri Surescan |
| Chiesi USA, INC. | $33.33 | 2024-2025 | Kengreal, Cleviprex |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.27 | 2024-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $29.15 | 2023 | Inpefa |
| Alexion Pharmaceuticals, INC. | $25.37 | 2022 | |
| Scpharmaceuticals INC. | $22.25 | 2025 | |
| Lilly USA, LLC | $20.05 | 2025 | Zepbound |
| Bridgebio Pharma, INC. | $19.60 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $16.40 | 2024 | Arcalyst |
| Livanova USA, INC. | $14.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.